Who is sponsoring NCT05385731?

NCT05385731 is sponsored by Leonardo A. Peyré-Tartaruga.

What drugs are being tested in NCT05385731?

Interventions in NCT05385731: Nordic Walking (NWG), Free Walking (FWG), Health Education (HEG).

What condition does NCT05385731 study?

NCT05385731 studies Multiple Sclerosis, Chronic Progressive, Multiple Sclerosis, Multiple Sclerosis, Primary Progressive, Multiple Sclerosis, Secondary Progressive.

Is NCT05385731 still recruiting?

NCT05385731 is currently status unknown. Last updated 23 May 2022.

Last reviewed 2022-05-23 · How we verify

NCT05385731: MUSCLE

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

MUSCLE - Nordic Walking in MUltiple SCLErosis

Status unknown NA Last updated 23 May 2022

What this trial tests

NA trial testing Nordic Walking (NWG) in Multiple Sclerosis, Chronic Progressive in 60 participants. Status unknown.

Timeline

2 August 2022

Primary endpoint
30 December 2022

30 December 2024

Quick facts

Lead sponsor	Leonardo A. Peyré-Tartaruga
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	triple
Primary purpose	treatment
Enrollment	60
Start date	2 August 2022
Primary completion	30 December 2022
Estimated completion	30 December 2024
Sites	1 location across Brazil

Drugs / interventions tested

Nordic Walking (NWG)
Free Walking (FWG)
Health Education (HEG)

Conditions studied

Multiple Sclerosis, Chronic Progressive — all drugs for Multiple Sclerosis, Chronic Progressive →
Multiple Sclerosis — all drugs for Multiple Sclerosis →
Multiple Sclerosis, Primary Progressive — all drugs for Multiple Sclerosis, Primary Progressive →
Multiple Sclerosis, Secondary Progressive — all drugs for Multiple Sclerosis, Secondary Progressive →

Sponsor

Leonardo A. Peyré-Tartaruga

Who can join

Adults 20 to 75, any sex, with Multiple Sclerosis, Chronic Progressive or Multiple Sclerosis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The aim of the study is to analyze the effects of Nordic Walking and free walking in the clinical-functional, postural balance, motor control, muscular echographic quality, and gait analysis (pendulum gait mechanism), in people with Multiple Sclerosis.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Multiple Sclerosis, Chronic Progressive

Currently open trials in the same condition.

NCT05359653 — Assessing Changes in Multi-parametric MRI in MS Patients Taking Clemastine Fumarate as a Myelin Repair Therapy · Phase 1, PHASE2 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05385731 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Leonardo A. Peyré-Tartaruga
Last refreshed: 23 May 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05385731.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing